Business Context and Reporting Period
Company: Neoleukin Therapeutics, Inc. (Note: Request metadata listed "Neurogene Inc.", but the filing identifies the registrant as Neoleukin Therapeutics, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: December 23, 2019
Event: Entry into a Material Definitive Agreement (Lease)
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on a new lease agreement.
| Metric | Value |
|---|---|
| Lease Commencement Date | December 23, 2019 |
| Lease Expiration Date | December 1, 2028 |
| Lease Term | Approximately 9 years |
| Space Size | Approximately 33,300 square feet |
| Location | 188 East Blaine Street, Seattle, Washington |
| Minimum Monthly Rent (Starting Dec 1, 2020) | $169,275 |
| Annual Rent Escalation | 2.5% per year |
Material Changes
The Company entered into a new lease for its future principal executive offices and research and development laboratory. This represents a significant commitment to fixed operating costs starting in 2020.
Outlook, Risks, and Contingencies
- Future Obligations: The Company is obligated to pay minimum rent of approximately $169,275 per month beginning December 1, 2020, with annual increases of 2.5%.
- Additional Costs: The Company is responsible for its share of annual operating expenses, taxes, and utilities.
- Termination: The lease expires on December 1, 2028, unless terminated earlier.
- Documentation: The full text of the lease will be filed as an exhibit to the Annual Report on Form 10-K for the year ending December 31, 2019.
Investor Verification Checklist
- Verify the Company's current cash position and liquidity to support the new monthly rent obligation of ~$169,275 starting in 2020.
- Review the upcoming Form 10-K for the full lease text to understand termination clauses and specific operating expense calculations.
- Confirm the status of the Company's research and development pipeline to ensure the new 33,300 sq. ft. facility aligns with operational needs.
- Check for any subsequent filings regarding the Company's ability to meet these new fixed costs.